Yannick ARLOT

Information

Group leader

Yannick ARLOT Group

+33 2 23 23 46 96

Villejean campus / Building 4 / Room _

Responsibilities

 

In a few words

The Von Hippel Lindau (VHL) gene is a tumor suppressor gene (TSG) that prevents tumorigenesis in a variety of tissues and organs. Germline loss-of-function mutations in this gene cause the von Hippel–Lindau (VHL) disease, an autosomal dominant cancer syndrome that predisposes to the development of retinal angioma, cerebellar and spinal hemangioblastoma, clear-cell renal cell carcinoma and pheochromocytoma and pancreatic cancer. The team investigate the  “non canonical” and “canonical” functions of pVHL  in tissues affected in the Vhl disease.

Major publications

  • Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).
    Martin B, Chesnel F, Delcros JG, Jouan F, Couturier A, Dugay F, Le Goff X, Patard JJ, Fergelot P, Vigneau C, Rioux-Leclerq N, Arlot-Bonnemains Y
    PLoS One. 2013 Jun  

    Overexpression of the polarity protein PAR-3 in clear cell renal cell carcinoma is associated with poor prognosis.
    Dugay F, Le Goff X, Rioux-Leclerq N, Chesnel F, Jouan F, Henry C, Cabillic F, Verhoest G, Vigneau C, Belaud-Rotureau MA and Arlot-Bonnemains Y. (YAB And MABR are co-last authors YAB is the correpsonding  author)
    Int J Cancer. 2014 May 

    The Von Hippel Lindau tumor suppressor gene: Uncovering the expression of the pVHL172 
    Chesnel F, Hascoet P, GagneJP, Couturier A,  Jouan F, Poirier G, Le Goff C, Vigneau C, Danger Y, Verite F , Le Goff X, & Arlot-Bonnemains
    Br J Cancer. 2015 Jun 2.

    Unconventional Functions of Mitotic Kinases in Kidney Tumorigenesis.
    Hascoet P, Chesnel F, Le Goff C, Le Goff X, Arlot-Bonnemains Y.
    Front Oncol. 2015 Oct   Review.

    PATENTS 

    Production d’anticorps monoclonaux dirigés contre la séquence protéique 172 de la proteine VHL humaine.
    HASCOET P, CHESNEL F, LE GOFF X, COUTURIER A & ARLOT-BONNEMAINS Y
    Cabinet Plasseraud  52 Rue  de la Victoire, Paris – Brevet N° 14305925.1 - 1402. reference : BEP :130403EPDP. Juin 2014

    Technologie de  culture organotypique de tissu tumoral
    JOUAN F & ARLOT-BONNEMAINS Y
    Cabinet Plasseraud  52 Rue  de la Victoire, Paris. Mai 2015

Subscribe to our newsletter